Start Date: 5/22/2023
Start Time: 9:00 AM EDT
Duration: 60 minutes
Abstract:
The webinar will feature participation from Gracell’s management team and key opinion leader Saad Z. Usmani, MD, MBA, FACP, Myeloma & Cellular Therapy Specialist, Hematologic Oncologist, Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, New York, NY. The focus of the discussion is on the Multiple Myeloma treatment landscape and highlights unmet clinical needs for relapsed/refractory Multiple Myeloma in the US. Following the discussion, there is a live question and answer session. The event will be available on ir.gracellbio.com.
If you're already registered for the Gracell Biotechnologies (Nasdaq:GRCL) Key Opinion Leader Webinar on Multiple Myeloma webcast, click below:
ALREADY REGISTERED?
Speakers
 Dr. William Cao Founder, Chairman and Chief Executive Officer Gracell Biotechnologies
 Dr. Wendy Li Chief Medical Officer Gracell Biotechnologies
 Dr. Kevin Xie Chief Financial Officer Gracell Biotechnologies
 Saad Z. Usmani, MD, MBA, FACP Hematologic Oncologist; Chief, Myeloma Service; Memorial Sloan Kettering Cancer Center Saad Z. Usmani, MD MBA FACP
Chief of Myeloma Service;
Member, Memorial Sloan Kettering Cancer Center, New York, NY;
Attending Physician, Myeloma, Cellular Therapy and Adult BMT Services
Dr. Saad Zafar Usmani is active in clinical and translational research and has research interests focus on plasma cell disorders—in particular, high-risk multiple myeloma. Dr. Usmani is board certified in internal medicine, medical oncology, and hematology, and he is a Fellow of the American College of Physicians. He holds membership and leadership roles on national/international committees, including the International Myeloma Working Group, the ALLIANCE Myeloma Committee (Chair), the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the American Society of Transplant & Cellular Therapy, and the National Cancer Institute Myeloma Steering Committee. Dr. Usmani has served as the Vice-Chair of the SWOG Myeloma Committee, and has served as chair for the ASH Scientific Committee on Plasma Cell Neoplasia, and the ASCO Scientific Committee on Plasma Cell Disorders. He has received several international awards recognizing his clinical and translational research contributions to the field, including the Celgene Young Investigator Award for Clinical Research, COMY Award for Excellence in Myeloma Research, LLS Scholar in Clinical Research, the International Myeloma Society Bart Barlogie Award for Clinical and Translational Research, and the LLS CDP Achievement Award. Dr. Usmani has authored/co-authored more than 230 peer-reviewed research manuscripts and over 300 abstracts at national and international meetings.
Dr. Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. He then joined the Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences in Little Rock, AR in 2010 as the Director of Developmental Therapeutics and Assistant Professor of Medicine. He was recruited to the Levine Cancer Institute/Atrium Health in 2013 as the inaugural Division Chief of Plasma Cell Disorders and Director of Clinical Research for Hematologic Malignancies where he built an internationally renowned myeloma program. He now serves as the Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center.
|
First Name
|
Last Name
|
Email Address
|
Company
|
Job Title
|
Country
|
|
|
|